Position in EXEL
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,770,929
+$1,508,104 QoQ
Shares Held
32,548
+431.1% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#274
of 751 holders
Holding Since
Jun 2020
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026AE Wealth Management LLC holds $11,774,403 across 15 Biotechnology names. EXEL ranks #3 (15.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
24,046 | $2,725,848 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,871 | $1,922,817 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
32,548 | $1,770,929 | |
| 4 | RPRX |
Royalty Pharma plc
|
29,628 | $1,661,236 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
3,184 | $767,232 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,094 | $682,131 | |
| 7 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
8,050 | $656,141 | |
| 8 | CYTK |
Cytokinetics Inc
|
5,316 | $452,857 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,770,929 | 32,548 | Shares | Other | 2026-08-03 | |
| 2026-03-31 | $262,825 | 6,128 | Shares | Other | 2026-05-13 | |
| 2025-12-31 | $250,702 | 5,720 | Shares | Other | 2026-01-26 | |
| 2023-12-31 | $245,777 | 10,245 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $222,542 | 10,185 | Shares | Sole | 2023-10-11 | |
| 2023-06-30 | $205,967 | 10,778 | Shares | Sole | 2023-07-10 | |
| 2023-03-31 | $254,018 | 13,087 | Shares | Sole | 2023-04-14 | |
| 2022-12-31 | $210,284 | 13,110 | Shares | Sole | 2023-01-31 | |
| 2020-06-30 | $676,590 | 28,500 | Shares | Sole | 2020-08-05 | |
| No filing history on record for this holder in this stock. | ||||||